Ameriprise Financial Inc. Boosts Stake in Structure Therapeutics Inc. (NASDAQ:GPCR)

Ameriprise Financial Inc. boosted its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 29.4% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,420,052 shares of the company's stock after buying an additional 322,601 shares during the period. Ameriprise Financial Inc. owned 2.48% of Structure Therapeutics worth $38,512,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of GPCR. ANTIPODES PARTNERS Ltd grew its position in shares of Structure Therapeutics by 115.0% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after purchasing an additional 553 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after purchasing an additional 1,122 shares in the last quarter. FNY Investment Advisers LLC purchased a new position in shares of Structure Therapeutics during the fourth quarter valued at about $40,000. Virtus ETF Advisers LLC grew its position in shares of Structure Therapeutics by 25.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after purchasing an additional 455 shares in the last quarter. Finally, Assetmark Inc. grew its position in shares of Structure Therapeutics by 72.3% during the fourth quarter. Assetmark Inc. now owns 2,271 shares of the company's stock valued at $62,000 after purchasing an additional 953 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Price Performance

Shares of NASDAQ:GPCR traded up $0.74 during trading hours on Friday, hitting $25.17. 826,116 shares of the company's stock traded hands, compared to its average volume of 934,882. Structure Therapeutics Inc. has a 1 year low of $13.22 and a 1 year high of $62.74. The business has a fifty day moving average price of $21.19 and a 200-day moving average price of $26.37. The firm has a market capitalization of $1.44 billion, a P/E ratio of -34.01 and a beta of -1.69.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). As a group, equities analysts predict that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GPCR has been the subject of a number of research analyst reports. Citigroup initiated coverage on Structure Therapeutics in a research report on Friday, May 2nd. They set a "buy" rating and a $60.00 price objective for the company. William Blair initiated coverage on Structure Therapeutics in a research report on Friday, February 28th. They issued an "outperform" rating for the company. Finally, HC Wainwright dropped their price target on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a research report on Monday, May 12th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $78.00.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.